Genmab Heads Into August Earnings With Bulls Firmly in Control

GMAB enters its August 6 earnings window with a straightforward story: short sellers have almost no presence, the analyst community is strongly bullish, and the stock has recovered sharply over the past month. The tension worth watching is whether the company can justify a clean setup after its last two quarterly prints both disappointed on the day.

The lending market is about as unthreatening as it gets for a biotech of this size. Borrow availability is effectively unlimited — the lending pool holds over 15 million shares against negligible demand, with fewer than 0.4% of lendable shares actually out on loan. Cost to borrow has drifted down roughly 10% over the past month to just 0.64%, near the lower end of its recent range. The ORTEX short score of 25.4 ranks in the 97th percentile for low short pressure — meaning almost no stock in the universe has less aggressive short positioning. This is not a story about squeeze dynamics or borrow stress. It is a story about a stock where the market's skeptics have largely stepped aside.

The Street is squarely in the bull camp. Thirteen analysts carry buy ratings against just two holds, with a consensus price target near DKK 2,392 — roughly 29% above the current price of DKK 1,852. No recent target changes are on record, so the bullish lean reflects a steady, not freshly-upgraded, conviction. Valuation multiples paint a moderate picture: the trailing P/E runs at roughly 20x, while EV/EBITDA is at 13.3x and compressing — down about 0.8 turns over the past month even as the stock has gained 13%. That compression suggests the rally has been partly earnings-driven rather than purely multiple expansion. Factor scores support the bull case selectively: 30-day EPS momentum ranks in the 85th percentile and the days-to-cover rank sits at the 83rd percentile, but EPS surprise scores poorly at the 8th percentile — a quiet reminder that Genmab has a recent history of underwhelming on the day.

That history is worth noting plainly. The May 7 print saw the stock fall 7.2% on the day and a further net 4.5% over the following week. The March result was softer — a 2.6% drop on the day, followed by a modest recovery. Two consecutive negative day-one reactions heading into a third print is the main friction point in an otherwise tidy setup. Institutional ownership is stable and concentrated: Orbis Investment Management holds 7.3% and has not changed its position, BlackRock recently added modestly to reach 6.8%, and the Allan & Gill Gray Foundation materially increased its stake — adding over 900,000 shares to reach 5.2% as of mid-June. That foundation-level accumulation is a signal of longer-term conviction rather than tactical positioning.

Insider activity is low-signal. A director sold a combined 526 shares in late May for roughly $142,000 in total — small in context and carrying a significance score of just 3 out of 10. The April equity awards to the CEO, CFO, and CMO were routine compensation grants at zero cost. Nothing in the insider register changes the picture materially. Among correlated peers, SION has been the week's standout, up nearly 11%, while RARE dropped over 10% — a wide dispersion that reflects the binary nature of small-cap biotech catalysts rather than any sector-wide directional move. Genmab itself was nearly flat on the week, off just 0.4%.

The August 6 print is the clearest near-term focus point — and specifically whether the company can break a two-quarter streak of day-one selling despite a broadly supportive setup heading in.